258 related articles for article (PubMed ID: 22031171)
1. Use of atorvastatin in systemic lupus erythematosus in children and adolescents.
Schanberg LE; Sandborg C; Barnhart HX; Ardoin SP; Yow E; Evans GW; Mieszkalski KL; Ilowite NT; Eberhard A; Imundo LF; Kimura Y; von Scheven E; Silverman E; Bowyer SL; Punaro M; Singer NG; Sherry DD; McCurdy D; Klein-Gitelman M; Wallace C; Silver R; Wagner-Weiner L; Higgins GC; Brunner HI; Jung L; Soep JB; Reed AM; Provenzale J; Thompson SD;
Arthritis Rheum; 2012 Jan; 64(1):285-96. PubMed ID: 22031171
[TBL] [Abstract][Full Text] [Related]
2. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.
Ardoin SP; Schanberg LE; Sandborg CI; Barnhart HX; Evans GW; Yow E; Mieszkalski KL; Ilowite NT; Eberhard A; Imundo LF; Kimura Y; Levy D; von Scheven E; Silverman E; Bowyer SL; Punaro L; Singer NG; Sherry DD; McCurdy DK; Klein-Gitelman M; Wallace C; Silver RM; Wagner-Weiner L; Higgins GC; Brunner HI; Jung L; Soep JB; Reed AM; Thompson SD;
Ann Rheum Dis; 2014 Mar; 73(3):557-66. PubMed ID: 23436914
[TBL] [Abstract][Full Text] [Related]
3. Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus.
Kiani AN; Post WS; Magder LS; Petri M
Rheumatology (Oxford); 2011 Nov; 50(11):2071-9. PubMed ID: 21875880
[TBL] [Abstract][Full Text] [Related]
4. Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study.
Plazak W; Gryga K; Dziedzic H; Tomkiewicz-Pajak L; Konieczynska M; Podolec P; Musial J
Arthritis Res Ther; 2011 Jul; 13(4):R117. PubMed ID: 21774822
[TBL] [Abstract][Full Text] [Related]
5. Lupus Atherosclerosis Prevention Study (LAPS).
Petri MA; Kiani AN; Post W; Christopher-Stine L; Magder LS
Ann Rheum Dis; 2011 May; 70(5):760-5. PubMed ID: 21177297
[TBL] [Abstract][Full Text] [Related]
6. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial.
Shukla A; Sharma MK; Jain A; Goel PK
Indian Heart J; 2005; 57(6):675-80. PubMed ID: 16521637
[TBL] [Abstract][Full Text] [Related]
7. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Davidson M; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Setze C; Carlson DM; Stolzenbach J
Cardiovasc Drugs Ther; 2012 Aug; 26(4):349-58. PubMed ID: 22622962
[TBL] [Abstract][Full Text] [Related]
8. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Davidson MH; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Mazzone T; Carlson DM; Williams LA; Kelly MT; Camp HS; Lele A; Stolzenbach JC
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1298-306. PubMed ID: 24743431
[TBL] [Abstract][Full Text] [Related]
9. Should children and adolescents with systemic lupus erythematosus be given statin therapy to prevent early atherosclerosis?
Ravelli A
Arthritis Rheum; 2012 Jan; 64(1):33-6. PubMed ID: 22031100
[No Abstract] [Full Text] [Related]
10. Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature.
Peng J; Dönnes P; Ardoin SP; Schanberg LE; Lewandowski L; ; Robinson G; Jury EC; Ciurtin C
Arthritis Rheumatol; 2024 Mar; 76(3):455-468. PubMed ID: 37786302
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial.
Fatemi A; Moosavi M; Sayedbonakdar Z; Farajzadegan Z; Kazemi M; Smiley A
Clin Rheumatol; 2014 Sep; 33(9):1273-8. PubMed ID: 24820145
[TBL] [Abstract][Full Text] [Related]
12. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort.
Schanberg LE; Sandborg C; Barnhart HX; Ardoin SP; Yow E; Evans GW; Mieszkalski KL; Ilowite NT; Eberhard A; Levy DM; Kimura Y; von Scheven E; Silverman E; Bowyer SL; Punaro L; Singer NG; Sherry DD; McCurdy D; Klein-Gitelman M; Wallace C; Silver R; Wagner-Weiner L; Higgins GC; Brunner HI; Jung L; Soep JB; Reed A;
Arthritis Rheum; 2009 May; 60(5):1496-507. PubMed ID: 19404953
[TBL] [Abstract][Full Text] [Related]
13. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.
van Leuven SI; Mendez-Fernandez YV; Wilhelm AJ; Wade NS; Gabriel CL; Kastelein JJ; Stroes ES; Tak PP; Major AS
Ann Rheum Dis; 2012 Mar; 71(3):408-14. PubMed ID: 21953346
[TBL] [Abstract][Full Text] [Related]
15. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
Bots ML; Visseren FL; Evans GW; Riley WA; Revkin JH; Tegeler CH; Shear CL; Duggan WT; Vicari RM; Grobbee DE; Kastelein JJ;
Lancet; 2007 Jul; 370(9582):153-160. PubMed ID: 17630038
[TBL] [Abstract][Full Text] [Related]
16. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
[TBL] [Abstract][Full Text] [Related]
17. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
18. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Taylor AJ; Kent SM; Flaherty PJ; Coyle LC; Markwood TT; Vernalis MN
Circulation; 2002 Oct; 106(16):2055-60. PubMed ID: 12379573
[TBL] [Abstract][Full Text] [Related]
19. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.
Smilde TJ; van Wissen S; Wollersheim H; Trip MD; Kastelein JJ; Stalenhoef AF
Lancet; 2001 Feb; 357(9256):577-81. PubMed ID: 11558482
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
